Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Screening Methods for Early Diagnosis of Lung Cancer in Current or Former Smokers

Multiple Cancer Types

This trial studies methods of detecting lung cancer at an earlier stage in current or former smokers with a special type of computed tomography (CT) scan and by testing genes and proteins in biospecimens (blood, urine, sputum, and tissue samples) collected at the time of bronchoscopy (examination of the airway). Analyzing these methods may provide an early detection of lung cancer in current or former smokers when it is more amenable to a cure.
Lung, Miscellaneous, Non Small Cell
N/A
Massion, Pierre
NCT01475500
VICCTHO1078

The COVID-19 and Cancer Consortium (CCC19) Registry

Miscellaneous

Miscellaneous
N/A
Warner, Jeremy
NCT04354701
VICCMD2032

Inherited CAncer REgistry (ICARE) Initiative

Miscellaneous

Miscellaneous
N/A
Pal, Tuya
NCT03231891
VICCMD1712

Donating Tissues for Research

Miscellaneous

Miscellaneous
N/A
Washington, Mary Kay
VICCBIO0478

REACH (Research, Education, Advocacy, Clinical Care and Health) for Survivorship Program: Long Term Effects for Survivors of Cancer

Multiple Cancer Types

Miscellaneous, Pediatrics
N/A
Esbenshade, Adam
VICCPED0710

Infectious Disease Outcomes in Pediatric Oncology Patients

Multiple Cancer Types

Miscellaneous, Pediatrics
N/A
Esbenshade, Adam
VICCPED14127

Survivorship in Patients Receiving Immune Checkpoint Inhibitors

Miscellaneous

Miscellaneous
N/A
Johnson, Douglas
VICCMEL15138

Integrating Comprehensive Precision Tobacco Treatment for Patients with Cancer

Miscellaneous

Miscellaneous
N/A
Pietenpol, Jennifer
VICCTHO1886

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Multiple Cancer Types

Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib administered in combination with everolimus once daily to pediatric participants with recurrent / refractory solid tumors. Phase 2, utilizing Simon's optimal 2-stage design, will be conducted to estimate the antitumor activity of lenvatinib in combination with everolimus in pediatric participants with selected recurrent / refractory solid tumors including Ewing sarcoma / peripheral primitive neuroectodermal tumor (pPNET), rhabdomyosarcoma, and high grade glioma (HGG) using objective response rate (ORR) at Week 16 as the outcome measure.
Miscellaneous, Pediatrics
I/II
Borinstein, Scott
NCT03245151
VICCPED2038

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: